L-Lysine is NOT Recommended for HSV-1 Infection
L-lysine supplementation should not be used for the prevention or treatment of HSV-1 infections, as the evidence demonstrates it is ineffective and lacks support from clinical guidelines.
Why Lysine is Not Recommended
Guideline Evidence is Clear
The CDC guidelines for HSV management 1, 2, 1, 2, 1 and the most recent 2022 CDC STI Treatment Guidelines 3 make no mention of lysine as a treatment option for HSV-1 or HSV-2. Instead, these guidelines consistently recommend:
- Acyclovir (200-800 mg orally, dosing varies by indication)
- Valacyclovir (500 mg - 1 g orally, dosing varies by indication)
- Famciclovir (250-500 mg orally, dosing varies by indication)
These antiviral medications are the only evidence-based treatments supported by randomized controlled trials and FDA approval 2, 3.
Research Evidence Shows Inconsistent and Weak Results
A systematic review specifically examining lysine for HSV prophylaxis 4 concluded that:
- Doses less than 1 g/day are ineffective
- Doses exceeding 3 g/day may provide subjective improvement only
- The evidence is insufficient to recommend lysine for HSV prophylaxis or treatment
Individual studies show conflicting results:
Studies suggesting possible benefit:
- One 1987 trial 5 using 3,000 mg/day (1,000 mg three times daily) showed reduced infection frequency and severity
- A 1984 study 6 found benefit when serum lysine exceeded 165 nmol/ml, requiring approximately 1,000 mg/day
Studies showing no benefit:
- A 1980 double-blind crossover study 7 found lysine had no effect on recurrence rate overall
- A 1984 study 8 showed 624 mg/day was ineffective, and even 1,248 mg/day had limited benefit
Theoretical Mechanism is Flawed
Lysine is theorized to work by antagonizing arginine, thereby inhibiting viral replication. However:
- This mechanism has not been validated in human HSV infections
- In vitro studies have not consistently demonstrated antiviral properties
- A systematic review in feline herpesvirus 9 (which shares similar biology) found lysine does not antagonize arginine and has no antiviral effect
What You Should Use Instead
For First Episode HSV-1 (Oral or Genital)
- Acyclovir 400 mg orally three times daily for 7-10 days 2
- Alternative: Valacyclovir 1 g orally twice daily for 7-10 days 2
- Alternative: Famciclovir 250 mg orally three times daily for 7-10 days 2
For Recurrent Episodes
- Acyclovir 400 mg orally three times daily for 5 days 1
- Alternative: Valacyclovir 500 mg twice daily for 3 days
- Alternative: Famciclovir 125 mg twice daily for 5 days
For Suppressive Therapy (Frequent Recurrences)
- Acyclovir 400 mg orally twice daily 1
- Alternative: Valacyclovir 500 mg once daily
- Alternative: Famciclovir 250 mg twice daily
Clinical Pitfalls to Avoid
- Do not recommend lysine as first-line therapy - Patients may delay effective antiviral treatment
- HSV-1 genital infections recur less frequently than HSV-2 - Consider this when deciding on suppressive therapy 2
- Topical acyclovir is substantially less effective than oral formulations and should be avoided 1
- If patients insist on trying lysine despite counseling, doses would theoretically need to exceed 3,000 mg/day based on the limited positive studies 5, but this is not evidence-based practice
Bottom Line
Use FDA-approved antivirals (acyclovir, valacyclovir, or famciclovir) as recommended by CDC guidelines 3. These medications have proven efficacy in reducing symptom duration, healing time, and transmission risk. Lysine lacks sufficient evidence, is not mentioned in any clinical guidelines, and should not be recommended for HSV-1 management.